This Article Abstract Full Text Full Text (PDF) View Related Journal Scan on Cardiosource Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Cohen-Solal, A. Articles by Mebazaa, A. Search for Related Content PubMed PubMed Citation Articles by Cohen-Solal, A. Articles by Mebazaa, A. Related Collections Related Articles

Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure

Alain Cohen-Solal, MD, PhD^_*,_*, Damien Logeart, MD^_*, Bidan Huang, PhD, Danlin Cai, PhD, Markku S. Nieminen, MD and Alexandre Mebazaa, MD, PhD^_*

^_* Hospital Lariboisière, Assistance Publique–Hopitaux de Paris, and Faculté de Médecine Denis Diderot, INSERM U 942, Paris, France
Abbott Laboratories, Abbott Park, Illinois
University Central Hospital, Helsinki, Finland

View larger version (22K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Mortality Rates According to BNP Changes Mortality rates at 31 and 180 days according to increases (>0%) and decreases in B-type natriuretic peptide (BNP) by 15%, 30%, 45%, and 60% between baseline and day 5.

View larger version (12K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Kaplan-Meier Survival Curves Kaplan-Meier survival curves (180 days) are shown according to decreases in B-type natriuretic peptide (BNP) between baseline and day-5 nonresponders (<30% BNP decrease from baseline) and responders (30% BNP decrease from baseline).